2021 American Transplant Congress
Kidney Transplant Outcomes Stratified by Race with a Calcineurin and Steroid Free Regimen
Pharmacy, Duke University Medical Center, Durham, NC
*Purpose: This study aimed to describe the outcomes, stratified by race, associated with belatacept and sirolimus immunosuppression after alemtuzumab induction.*Methods: This was a retrospective, single-center…2020 American Transplant Congress
Conversion to Sirolimus to Prevent Recurrent Cytomegalovirus Infection/Disease: A Prospective and Randomized Trial
Hospital do Rim - UNIFESP, São Paulo, Brazil
*Purpose: Recurrent cytomegalovirus (CMV) infection occurs in 30-35% of kidney transplant recipients after completion of treatment and/or preemptive therapy. There is no consensus on the…2020 American Transplant Congress
Immuno-Modulation of Primed Xenogeneic T Cell Response by mTOR Blockade of T Cells and Porcine Endothelial Cells
Surgery, Duke University, Durham, NC
*Purpose: Porcine vascular endothelial cells (PECs) play a central role in xeno-recognition and costimulation. The objectives of this study were to characterize the immuno-phenotype of…2020 American Transplant Congress
Sirolimus Combined with Low-Dose Calcineurin Inhibitor in Kidney Transplant Recipients from Expanded Criteria Donors
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: To evaluate the efficacy and safety of conversion from calcineurin inhibitor-based immunosuppressive regimen to sirolimus combined with low-dose calcineurin inhibitor in recipients with abnormal…2020 American Transplant Congress
The Impact of Sirolimus on Weight Gain Post Heart Transplant
*Purpose: Obesity is common after heart transplant (HT), resulting in increased risk of new onset diabetes, all-cause and cardiovascular mortality and graft failure. Immunosuppressants (ISN)…2020 American Transplant Congress
Long Term Effect of Tacrolimus Conversion to Sirolimus with Prednisone-Free Regimen in Kidney Allograft Outcomes: A Dynamic Analysis of Graft Survival Using Joint Modeling
*Purpose: Findings on long-term impacts of the mammalian target of rapamycin inhibitor inhibitors on kidney allograft are scarce and mixed. A joint modeling approach can…2019 American Transplant Congress
A Clinical Pharmacogenetic Model to Predict the Efficacy of Sirolimus during the Early Administration in Renal Transplant Recipients
No.300 Guangzhou Road of Nanjing, Nanjing, China
*Purpose: This study was to develop a clinical pharmacogenetic model to predict the efficacy of sirolimus during the early administration in renal transplant recipients. 70…2019 American Transplant Congress
Sirolimus (SRL) versus Everolimus (EVR) versus Mycophenolate (MPA) in Kidney Transplant Recipients Receiving Anti-Thymocyte Globulin Induction (r-ATG), Tacrolimus (TAC), and Prednisone
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: TAC and MPA combination is considered the standard of care immunosuppressive regimen in the majority of transplant centers worldwide. Yet, given the lack of…2019 American Transplant Congress
Comparison of Initial Sirolimus (SRL) and Everolimus (EVR) Exposure Patterns in Kidney Transplant Recipients
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Despite distinct pharmacokinetic properties, SRL and EVR bind to the same intracellular target protein, suggesting that equivalent blood concentrations may exert similar pharmacodynamic effect.*Methods:…2019 American Transplant Congress
Slowed Progression of Maximal Intimal Thickening by Intravascular Ultrasound after Initiation of Sirolimus
1Children's Hospital Colorado, Aurora, CO, 2University of Florida Health, Gainesville, FL
*Purpose: Evidence in adult heart transplant (HT) patients (pt) shows that initiating sirolimus (SRL) slows progression of cardiac allograft vasculopathy (CAV) measured by intravascular ultrasound…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »